Advances in Liquid Biopsy for Early Screening and Monitoring of Gastrointestinal Cancers
Abstract
on non-invasive biomarkers such as ctDNA, CTCs, exosomes, and miRNAs. These biomarkers show promise in improving early diagnosis,
tracking treatment response, and detecting recurrence. While ctDNA enables real-time monitoring, CTCs and exosomal miRNAs help reveal
tumor dynamics. Despite its potential, challenges like low biomarker levels in early stages and lack of standardization limit clinical application. Further technological development and protocol refinement are needed to fully realize its value in personalized cancer management.
Keywords
Full Text:
PDFReferences
[1] Zhou H, Zhu L, Song J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol
Cancer. 2022;21(1):86. doi:10.1186/s12943-022-01556-2
[2] Yamada T, Matsuda A, Koizumi M, et al. Liquid biopsy for the management of patients with colorectal cancer. Digestion. 2019;
99(1):39-45. doi:10.1159/000494411
[3] Yu P, Chen P, Wu M, et al. Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer. Genome
Med. 2024;16(1):79. doi:10.1186/s13073-024-01352-1
[4] Okuno K, Watanabe S, Roy S, et al. A liquid biopsy signature for predicting early recurrence in patients with gastric cancer. Br J Cancer. 2023;128(6):1105-1116. doi:10.1038/s41416-022-02138-1
[5] Herrera-Pariente C, Montori S, Llach J, Bofill A, Albeniz E, Moreira L. Biomarkers for gastric cancer screening and early diagnosis.
Biomedicines. 2021;9(10):1448. doi:10.3390/biomedicines9101448
[6] Okuno K, Watanabe S, Hur H, et al. An exosome-based liquid biopsy signature for therapeutic response prediction in metastatic gastric
cancer. Clin Transl Med. 2024;14(7):e1629. doi:10.1002/ctm2.1629
[7] Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer. Int J Mol Sci. 2022;23(2):852. doi:10.3390/
ijms23020852
[8] Weinberg DS, Barkun A. Liquid biopsy for colorectal cancer screening: Not so bloody fast. Gastroenterology. 2024;167(2):208-210.
doi:10.1053/j.gastro.2024.03.022
[9] Yang W, Han Y, Zhao X, et al. Advances in prognostic biomarkers for esophageal cancer. Expert Rev Mol Diagn. 2019;19(2):109-119. d
oi:10.1080/14737159.2019.1563485
[10] Schoofs K, Philippron A, Avila Cobos F, et al. Comprehensive RNA dataset of tissue and plasma from patients with esophageal cancer
or precursor lesions. Sci Data. 2022;9(1):86. doi:10.1038/s41597-022-01176-x
[11] Uhe I, Hagen ME, Ris F, Meyer J, Toso C, Douissard J. Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A
systematic review. World J Gastrointest Oncol. 2021;13(11):1799-1812. doi:10.4251/wjgo.v13.i11.1799
[12] Khachfe HH. Use of liquid biopsies in gastrointestinal cancers. World J Gastrointest Oncol. 2021;13(9):1210-1212. doi:10.4251/wjgo.
v13.i9.1210
[13] Croitoru VM, Cazacu IM, Popescu I, et al. Clonal Hematopoiesis and Liquid Biopsy in Gastrointestinal Cancers. Front Med (Lausanne).
2021;8:772166. doi:10.3389/fmed.2021.772166
[14] Baca SC, Seo JH, Davidsohn MP, et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2023;29(11):2737-2741.
doi:10.1038/s41591-023-02605-z
[15] Zhang C, Li T, Zhao Q, et al. Advances and Prospects in Liquid Biopsy Techniques for Malignant Tumor Diagnosis and Surveillance.
Small. 2024;20(44):e2404709. doi:10.1002/smll.202404709
DOI: http://dx.doi.org/10.70711/pmr.v2i6.7253
Refbacks
- There are currently no refbacks.
